PROCEPT BioRobotics PRCT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
PROCEPT BioRobotics (PRCT) Business Model and Operations Summary
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Key Insights
PROCEPT BioRobotics (PRCT) Core Market Data and Business Metrics
Latest Closing Price
$57.09Market Cap
$3.14 BillionPrice-Earnings Ratio
-27.71Total Outstanding Shares
54.82 Million SharesTotal Employees
756Dividend
No dividendIPO Date
September 15, 2021SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
150 Baytech Drive, San Jose, CA, 95134
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-91.76 Million |
| Net Cash Flow From Financing Activities, Continuing | $172.87 Million |
| Net Cash Flow From Investing Activities | $-17.48 Million |
| Net Cash Flow, Continuing | $63.63 Million |
| Net Cash Flow From Operating Activities, Continuing | $-91.76 Million |
| Net Cash Flow From Investing Activities, Continuing | $-17.48 Million |
Income Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Cost Of Revenue | $79.93 Million |
| Income/Loss From Continuing Operations Before Tax | $106.08 Million |
| Net Income/Loss Attributable To Parent | $-103.71 Million |
| Costs And Expenses | $286.22 Million |
| Net Income/Loss | $-103.71 Million |
| Benefits Costs and Expenses | $0 |
Comprehensive Income
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-103.73 Million |
| Other Comprehensive Income/Loss | $-77.78 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-103.70 Million |
Balance Sheet
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $79.73 Million |
| Other Non-current Assets | $24.78 Million |
| Inventory | $43.87 Million |
| Long-term Debt | $51.40 Million |
| Equity | $251.78 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||